








CLAIMS


1. A compound selected from ~~the group consisting of:~~





And/or a pharmaceutically acceptable salts and/or solvates thereof.


2. The compound of claim 1 selected from:



and pharmaceutically acceptable salts and solvates thereof.

5


3. The compound of claim 1 selected from:



and pharmaceutically acceptable salts and solvates thereof.


10

4. The compound of claim 1 selected from:




and pharmaceutically acceptable salts and solvates thereof.

5. The compound of claim 1 selected from:




and pharmaceutically acceptable salts and solvates thereof.

6. The compound of claim 1 selected from:



and pharmaceutically acceptable salts and solvates thereof.


7. ~~The compound of claim 1 selected from:~~



~~and pharmaceutically acceptable salts and solvates thereof.~~

5

8. ~~The compound of claim 1 selected from:~~



~~and pharmaceutically acceptable salts and solvates thereof.~~

10 92. A pharmaceutical composition comprising (i) a compound, or a pharmaceutically acceptable salt or solvate thereof, as claimed in ~~any one of~~ claims 1, ~~to 8~~ and (ii) at least one pharmaceutically acceptable carrier, diluent or excipient.

15 103. A compound, or a pharmaceutically acceptable salt or solvate thereof, as claimed in ~~any one of~~ claims 1, ~~to 8~~ for use in medicine.

~~114.~~ The use of a compound as claimed in ~~any one of claims 1 to 8~~, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated; wherein the disease or condition in which plasma kallikrein activity is implicated is selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, bleeding from post operative surgery, retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema, and retinal vein occlusion.-

~~125.~~ A compound, or pharmaceutically acceptable salt or solvate thereof, as claimed in ~~any one of claims 1 to 8~~ for use in a method of treatment of a disease or condition in which plasma kallikrein activity is implicated.

~~136.~~ ~~The use of claim 11; or the~~The compound, or pharmaceutically acceptable salt or solvate thereof, for use according to claim ~~512~~; wherein the disease or condition in which plasma kallikrein activity is implicated is selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery and bleeding from post operative surgery.

~~147.~~ The use of claim ~~411~~; or the compound, or pharmaceutically acceptable salt or solvate thereof, for use according to claim ~~512~~; wherein the the disease or condition mediated by plasma kallikrein is hereditary angioedema.

~~158.~~ The use of claim ~~411~~; or the compound, or pharmaceutically acceptable salt or solvate thereof, for use according to claim ~~512~~; wherein the the disease or condition mediated by plasma kallikrein is diabetic macular edema.

~~169~~. The use of claim ~~441~~; or the compound, or pharmaceutically acceptable salt or solvate thereof, for use according to claim ~~125~~; wherein the disease or condition in which plasma kallikrein activity is implicated is selected from retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

5

~~1710~~. The use of claim ~~144~~; or the compound, or pharmaceutically acceptable salt or solvate thereof, for use according to claim ~~125~~; wherein the disease or condition in which plasma kallikrein activity is implicated is retinal vein occlusion.